---
title: Research
permalink: /gcgs/research/
description: ""
---
### Completed Trials (both are industry trials):

*   Phase 3, double blind, randomized, controlled, study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 mth) in healthy adult female subjects aged 26 years and above (HPV-015) (2009-2014) **(NCT00294047)** For more information on the trial, please access the link, [https://clinicaltrials.gov/ct2/show/NCT00294047](https://clinicaltrials.gov/ct2/show/NCT00294047).
*   A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (Morab-0003) in Combination with Carboplatin and Taxane in Subjects with Platinum-Sensitive-Ovarian Cancer in First Relapse. (2009-2012) **(NCT00849667)** For more information on the trial, please access the link, [https://clinicaltrials.gov/ct2/show/NCT00849667](https://clinicaltrials.gov/ct2/show/NCT00849667).

### Ongoing Trials:

*   Integrated Molecular Analysis of Cancer in Gynaecologic Oncology (IMAC-GO) – 2014 - **_(NCT02078544)_** For more information on the trial, please access the link, [https://clinicaltrials.gov/ct2/show/NCT02078544](https://clinicaltrials.gov/ct2/show/NCT02078544).
*   A Randomized Phase II / III Trial of Intravenous (IV) paclitaxel weekly plus (IV) Carboplatin once every 3 weeks versus IV paclitaxel weekly plus intraperitoneal (IP) carboplatin once every 3 weeks in women with epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer – 2014, collaboration with Japan (GOTIC and JGOG) - **_(NCT01506856)_** For more information on the trial, please access the link, [https://clinicaltrials.gov/ct2/show/NCT01506856](https://clinicaltrials.gov/ct2/show/NCT01506856).
*   An Open-Label, Single-Arm Phase 2 Clinical Trial of Regorafenib in Patients with Multiply Recurrent Epithelial Ovarian Cancer – 2016 – **_(NCT02736305)_** For more information on the trial, please access the link, [https://clinicaltrials.gov/ct2/show/NCT02736305](https://clinicaltrials.gov/ct2/show/NCT02736305).
*   Phase II Study of Vinorelbine in Stem-A/C5-like Subtype Platinum Resistant Ovarian Cancer (VIP trial) – 2017, collaboration with Australia (ANZGOG) – **_(_****_NCT03188159)_** For more information on the trial, please access the link, [https://clinicaltrials.gov/ct2/show/NCT03188159](https://clinicaltrials.gov/ct2/show/NCT03188159).
*   A Phase Ib/IIa Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy in Patients with Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin – 2017 – **_(NCT03100006)_** For more information on the trial, please access the link, [https://clinicaltrials.gov/ct2/show/NCT03100006](https://clinicaltrials.gov/ct2/show/NCT03100006).
*   A Multicentre Phase II randomised trial of MEDI4736 (DURVALUMAB) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinomas – 2018, collaboration with Korea (KGOG) and Australia (ANZGOG) **_(_****_NCT03405454)_** For more information on the trial, please access the link, [https://clinicaltrials.gov/ct2/show/NCT03405454](https://clinicaltrials.gov/ct2/show/NCT03405454).
*   A phase I study of low dose whole abdominal radiation therapy (LDWART) with weekly paclitaxel for platinum resistant ovarian cancer _**(NCT02545010)**_ For more information on the trial, please access the link, [https://clinicaltrials.gov/ct2/show/NCT02545010](https://clinicaltrials.gov/ct2/show/NCT02545010). (Phase I completed and published, pending Phase II)
*   Phase I study of Combined Medi4736 (Durvalumab, PD-L1 inhibitor), PARP inhibitor (Olaparib), and AKT inhibitor (AZD5363) in Solid Tumours (MediPAC Study) - 2018- _**(NCT03772561)**_ For more information on the trial, please access the link, [https://www.clinicaltrials.gov/ct2/show/NCT03772561?term=NCT03772561&draw=2&rank=1](https://www.clinicaltrials.gov/ct2/show/NCT03772561?term=NCT03772561&draw=2&rank=1). 
*   Phase I/II Clinical Trial to Evaluate Platinum-based Chemotherapy, Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy in Patients with Platinum Sensitive Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-02) - 2020 - _**(NCT04620954)**_. For more information on the trial, please access the [link, https://www.clinicaltrials.gov/ct2/show/NCT04620954?term=Orion02&draw=2&rank=1](https://www.clinicaltrials.gov/ct2/show/NCT04620954?term=Orion02&draw=2&rank=1).
*   A single-arm phase II study of **O**laparib maintenance with **Pe**mbrolizumab & **B**evacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01) - 2020, collaboration with Korea (KGOG) - _**(NCT04361370)**_. For more information on the trial, please access the link, [https://www.clinicaltrials.gov/ct2/show/NCT04361370?term=NCT04361370&draw=2&rank=1](https://www.clinicaltrials.gov/ct2/show/NCT04361370?term=NCT04361370&draw=2&rank=1).
*   Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E) - 2020 - _**(NCT04269200)**_. For more information on the trial, please access the link, [https://www.clinicaltrials.gov/ct2/show/NCT04269200?term=DUO-E+trial&draw=2&rank=1](https://www.clinicaltrials.gov/ct2/show/NCT04269200?term=DUO-E+trial&draw=2&rank=1).
    
*   A Multicentre Phase II trial of  Lenvatinib plus PembrolizumAb in Recurrent gynaecological clear cell Adenocarcinomas (LARA) - 2021 - _**(NCT04699071)**_. For more information on the trial, please access the link, [https://www.clinicaltrials.gov/ct2/show/NCT04699071?term=LARA&cntry=SG&draw=2&rank=1](https://www.clinicaltrials.gov/ct2/show/NCT04699071?term=LARA&cntry=SG&draw=2&rank=1).
*   Phase III Randomized, Open-label, Active-controlled Study of Alpelisib Plus Olaparib in Platinum-Resistant, High-grade Serous OC (EPIK-O) - 2021 - _**(NCT04729387)**_. For more information on the trial, please access the link, [https://www.clinicaltrials.gov/ct2/show/NCT04729387?term=NCT04729387&draw=2&rank=1](https://www.clinicaltrials.gov/ct2/show/NCT04729387?term=NCT04729387&draw=2&rank=1).
*   Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301) - 2021 - _**(NCT04697628)**_. For more information on the trial, please access the link, [https://www.clinicaltrials.gov/ct2/show/NCT04697628?term=NCT04697628&draw=2&rank=1](https://www.clinicaltrials.gov/ct2/show/NCT04697628?term=NCT04697628&draw=2&rank=1).